2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究*

doi:10.3969/j.issn.1672-5069.2024.05.023

摘要/Abstract

摘要： 目的探讨超声二维剪切波弹性成像(2D-SWE)技术联合肝纤维化-4因子指数(FIB-4)和血清血管内皮生长因子(VEGF)水平评估乙型肝炎肝硬化患者食管静脉曲张(EV)的价值。方法 2020年6月～2023年6月我院收治的乙型肝炎肝硬化患者117例,常规行胃镜检查了解EV发生情况,采用超声2D-SWE技术检测肝硬度(LSM)和脾硬度(SSM)。根据临床检测结果计算FIB-4,采用ELISA法检测血清VEGF水平。应用受试者工作特征曲线(ROC)并计算曲线下面积(AUC)评估各指标预测肝硬化患者EV发生的效能。结果经胃镜检查发现,本组117例乙型肝炎肝硬化患者中非EV者42例(35.9%)和发生EV者75例(64.1%);EV组LSM、SSM、FIB-4和血清VEGF水平分别为(19.4±5.4)kPa、(42.5±9.5)kPa、(4.7±1.6)和(168.6±50.4)pg/mL,显著高于非EV组【分别为(14.2±4.7)kPa、(30.9±8.6)kPa、(2.6±0.9)和(130.9±39.3)pg/mL,P<0.05】;经ROC曲线分析,LSM、SSM、FIB-4和血清VEGF水平联合评估乙型肝炎肝硬化患者EV发生(其截断点分别为16.0 kPa、38.8 kPa、3.7和142.9 pg/mL)的AUC为0.954,其灵敏度和特异度分别为92.0%和85.7%,显著优于各指标单独预测(P<0.05)。结论应用2D-SWE技术检测LSM和SSM联合FIB-4和血清VEGF水平能够帮助初步判断乙型肝炎肝硬化患者EV的发生,值得临床进一步验证。

关键词: 肝硬化, 食管静脉曲张, 二维剪切波弹性成像, 肝纤维化-4因子指数, 血管皮内生长因子, 诊断

Abstract: Objective The aim of this study was to evaluate the existence of esophageal varices (EV) by two-dimensional shear wave elastography (2D-SWE) technology, fibrosis-4 factor index (FIB-4) and serum vascular endothelial growth factor (VEGF) levels in patients with hepatitis B-induced liver cirrhosis(LC). Methods 117 patients with hepatitis B-induced LC were enrolled in our hospital between June 2020 and June 2023, and they all underwent routine gastroscopy to determine the occurrence of EV. The liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) were detected by 2D SWE technology. The FIB-4 was calculated based on blood biochemical results and demographic data. Serum VEGF level was assayed by ELISA. The receiver operating characteristic curve (ROC) was drawn and the area under the curve (AUC) were calculated to evaluate the diagnostic efficacy of each parameter on EV happening in patients with hepatitis B-induced LC. Results The gastroscopy found EV in 42 cases (35.9%) and no EV in 75 cases (64.1%) in our 117 patients with LC; the LSM, SSM, FIB-4 score and serum VEGF level in patients with EV were (19.4±5.4)kPa, (42.5±9.5)kPa, (4.7±1.6) and (168.6±50.4)pg/mL, all significantly higher than [(14.2±4.7)kPa, (30.9±8.6)kPa,(2.6±0.9) and (130.9±39.3)pg/mL, respectively, P<0.05] in patients without EV; the ROC analysis showed that the AUC was 0.954, with the sensitivity and specificity of 92.0% and 85.7%, respectively, when the LSM, SSM,FIB-4 and serum VEGF level were combined to predict the occurrence of EV (the cut-off-value were 16.0 kPa, 38.8 kPa, 3.7 and 142.9 pg/mL, respectively), much superior to any parameter alone (P<0.05). Conclusion The application of 2D-SWE technology to detect LSM and SSM and their combination of FIB-4 score and serum VEGF level could predict the occurrence of EV in patients with hepatitis B-induced LC, which needs further clinical verification.

Key words: Liver cirrhosis, Esophageal varices, Two-dimensional shear wave elastography, Liver fibrosis-4 factor index, Vascular endothelial growth factor, Diagnosis

信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.

Xin Liangliang, Wen Zhi. Assessment of esophageal varices by 2D-SWE technology, FIB-4 and serum VEGF level in patients with hepatitis B-induced liver cirrhosis[J]. Journal of Practical Hepatology, 2024, 27(5): 737-740.

参考文献

[1] 毛会娟,王卫芳,姚佳,等.肝纤维化指标在乙型肝炎肝硬化及进展程度中的意义.中华医院感染学杂志,2021,31(17):2561-2565.
[2] 朱亭亭,李正鑫,袁杰,等.慢性肝病不同肝纤维化阶段的肝脏体积及其病理变化特点.中华肝脏病杂志,2024,32(6):517-524.
[3] Lesmana CRA, Raharjo M, Gani RA. Managing liver cirrhotic complications: Overview of esophageal and gastric varices. Clin Mol Hepatol, 2020, 26(4):444-460.
[4] Salman AA, Shaaban HE, Atallah M, et al. Long-term outcome after endoscopic ligation of acute esophageal variceal bleeding in patients with liver cirrhosis. Acta Gastroenterol Belg, 2020, 83(3):373-380.
[5] Takehara T, Sakamori R. Remaining challenges for the noninvasive diagnosis of esophageal varices in liver cirrhosis. Esophagus, 2020, 17(1):19-24.
[6] Ozturk A, Olson MC, Samir AE, et al. Liver fibrosisassessment: MR and US elastography. Abdom Radiol (NY), 2022, 47(9):3037-3050.
[7] Aquino-Matus J, Uribe M, Chavez-Tapia N. Liver and spleen elastography as predictor of portal hypertension and esophageal varices. Minerva Gastroenterol (Torino), 2021, 67(2):122-128.
[8] Xuan J, Shi Z. Shear wave elastography measured liver stiffness-spleen size-to-platelet ratio for the prediction of high-risk oesophageal varices: a meta-analysis. Eur J Gastroenterol Hepatol, 2023, 35(7):753-760.
[9] Liu H, Chen P, Jiang B, et al. Thevalue of platelet parameters and related scoring system in predicting esophageal varices and collateral veins in patients with liver cirrhosis. J Clin Lab Anal, 2021, 35(3):e23694.
[10] Allaire M, Rudler M, Thabut D. Portal hypertension and hepatocellular carcinoma: des liaisons dangereuses. Liver Int, 2021, 41(8):1734-1743.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[12] 徐小元,丁惠国,贾继东等.肝硬化门静脉高压食管胃静脉曲张出血的防治指南.实用肝脏病杂志,2016,19(5):641-656.
[13] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会消化内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血的防治指南.中华内科杂志,2023,62(1):7-22.
[14] Payal B, M S. Ratio of platelet count to splenic diameter as a predictor of esophageal varices in cirrhosis of liver. J Assoc Physicians India, 2022, 70(4):11-12.
[15] Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology, 2021, 73(1):366-413.
[16] Fierbinteanu-Braticevici C, Tribus L, Peagu R, et al. Spleen stiffness as predictor of esophageal varices in cirrhosis of different etiologies. Sci Rep, 2019, 9(1):16190.
[17] Huang Z, Zhou J, Lu X, et al. How does liver steatosis affect diagnostic performance of 2D-SWE.SSI: assessment from aspects of steatosis degree and pathological types. Eur Radiol, 2021, 31(5):3207-3215.
[18] Itakura J, Kurosaki M, Setoyama H, et al. Applicability of APRI and FIB-4 asa transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol, 2021, 56(5):470-478.
[19] Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy. JHEP Rep, 2021, 3(4):100316.
[20] Shukla A, Giri S. Portal vein thrombosis in cirrhosis. J Clin Exp Hepatol, 2022, 12(3):965-979.
[21] 陈斯良,肖承江,金思一,等.肝硬化门静脉高压TIPS术后血浆脂多糖变化对血小板释放血管内皮生长因子和血小板反应蛋白-1的影响.中华肝脏病杂志,2022,30(2):207-212.
[22] Kumar A, Lal SB, Bhatia A, et al. Role of noninvasive tools for prediction of clinically evident portal hypertension in children. Eur J Gastroenterol Hepatol, 2020, 32(8):931-937.
[23] Segna D, Mendoza YP, Lange NF, et al. Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after baveno vii - an update. Dig Liver Dis, 2023, 55(3):326-335.
[24] Upadhyay P, Khanna R, Sood V, et al. Splenic stiffness is the best predictor of clinically significant varices in children with portal hypertension. J Pediatr Gastroenterol Nutr, 2023, 76(3):364-370.
[25] Karagiannakis DS, Stefanaki K. Spleen stiffness: a predictive factor of dismal prognosis in liver cirrhosis. Clin J Gastroenterol, 2023, 16(2):121-129.

2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*

Assessment of esophageal varices by 2D-SWE technology, FIB-4 and serum VEGF level in patients with hepatitis B-induced liver cirrhosis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[3]	杨逸铭, 李晓环, 刘玉品, 欧金龙, 黎胜, 石美凤, 汪印强. FibroScan、MRI-PDFF和FAST评分识别高危非酒精性脂肪性肝炎患者临床应用研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 701-704.
[4]	谢爱萍, 赵景, 蒋祁明, 何秀波. 超声声衰减系数与受控衰减参数联合肝脏硬度检测诊断NAFLD患者NASH发生效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 705-708.
[5]	任艳, 孔明, 徐曼曼, 白丽, 陈煜. 瞬时弹性成像技术和无创诊断模型诊断原发性胆汁性胆管炎患者肝纤维化效能研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 725-728.
[6]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.
[7]	田琳, 康颖, 崔洁, 石颖鹏. 内镜下套扎联合奥曲肽和凝血酶治疗肝硬化并发食管胃静脉曲张出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 745-748.
[8]	李双玲, 刘丽, 陈艺, 李坤. 富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 749-752.
[9]	连作勤, 王世明, 张甲, 李付平. 富马酸丙酚替诺福韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效和安全性评估^*[J]. 实用肝脏病杂志, 2024, 27(5): 753-756.
[10]	昝双江, 于恬, 戴静. 直接抗病毒药物治疗丙型肝炎肝硬化患者血清血小板生成素和外周血血小板计数变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 757-760.
[11]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[12]	陈思彤, 卫小蝶, 韦新焕, 郭海清, 张晶. 代谢功能障碍相关脂肪性肝病诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 481-483.
[13]	柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.
[14]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[15]	罗洪霞, 李静秋, 李媛媛, 冯国隽, 余霞. 超重/肥胖非酒精性脂肪性肝病儿童磁共振质子密度脂肪分数检测意义研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 527-530.